Related Experiment Videos
Tamoxifen as a potential treatment of glioma
L Mastronardi1, F Puzzilli, A Ruggeri
1Sandro Pertini Hospital, Division of Neurosurgery, Rome, Italy.
Abstract:
Cerebral gliomas have a poor survival time even after multimodal treatment, because of the unavoidable recurrence of tumor. Several trials with a combination of old and new chemotherapics have been performed, but survival time remains generally less than 12 months. Tamoxifen (TAM) has recently been shown to inhibit the growth rate of established and low-passage human glioma cell lines. Furthermore, this drug has enabled stabilization of the clinical and radiographic picture in selected patients with recurrent glioma. Here we review published data to discuss a potential role of TAM in the multimodal postoperative treatment of cerebral gliomas.
Insights
Tamoxifen (TAM) shows promise in treating cerebral gliomas by inhibiting tumor growth and stabilizing patient conditions. This review explores TAM's potential role in multimodal postoperative treatment for better glioma outcomes.
Area of Science:
- Neuro-oncology
- Cancer therapy
- Pharmacology
Background:
- Cerebral gliomas have a poor prognosis with survival typically under 12 months, even with multimodal treatment.
- Tumor recurrence is a significant challenge in managing cerebral gliomas.
- Current chemotherapeutic approaches offer limited improvements in survival rates.
Purpose of the Study:
- To review published data on Tamoxifen (TAM) for cerebral gliomas.
- To discuss the potential role of TAM in multimodal postoperative treatment.
- To evaluate TAM's efficacy in inhibiting glioma cell growth and stabilizing patient conditions.
Main Methods:
- Review of published scientific literature.
- Analysis of studies on Tamoxifen's effect on human glioma cell lines.
- Examination of clinical data from patients with recurrent glioma treated with Tamoxifen.
Main Results:
- Tamoxifen (TAM) demonstrated inhibition of growth in established and low-passage human glioma cell lines.
- Clinical and radiographic stabilization was observed in selected patients with recurrent glioma receiving TAM.
- Published data suggests a potential therapeutic benefit of TAM.
Conclusions:
- Tamoxifen (TAM) exhibits anti-glioma properties.
- TAM may play a role in the multimodal postoperative treatment of cerebral gliomas.
- Further investigation into TAM as a glioma treatment is warranted.